Hexahydro-1-(2-nitrophenyl)-5-(phenylmethyl)-1H-1,2,5-triazepine | 125605-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Hexahydro-1-(2-nitrophenyl)-5-(phenylmethyl)-1H-1,2,5-triazepine
• 英文别名: 5-benzyl-1-(2-nitrophenyl)-1,2,5-triazepane
• CAS: 125605-24-5
• 化学式: C₁₇H₂₀N₄O₂
• 分子量: 312.371
• InChiKey: VXRGHAZJHYOZSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Hexahydro-1-(2-nitrophenyl)-5-(phenylmethyl)-1H-1,2,5-triazepine 、 乙酸乙酯 在 钯 乙二醇二甲醚 、 1,1-carbonyldiimidazole 、 氯仿 、 crude titled product 、 Heptane chloroforme 作用下， 以 乙二醇二甲醚 为溶剂， 以gave pure product, mp=127°-128°的产率得到2,3,4,5-Tetrahydro-3-(Phenylmethyl)-1H[1,2,5]Triazepino[1,2-a]-[1,2,4]Benzotriazine-7(8H)-One
  参考文献：
  名称：

  2,3,4,5-tetrahyd

  摘要：

  本文披露了新型的1,2,3,4,5,6-六氢[1,3,6]三唑环[1,2-a]苯并咪唑的I和II式：其中R.sup.1可能是苯基，m-或p-硝基苯基，m-或p-甲基磺酰氨基苯基，萘基，萘单取代硝基或甲基磺酰氨基，苯并呋喃基，2-嘧啶基，2-或4-吡啶基，2-或4-萘啉基，吡嗪基，异喹啉基或喹啉基；R.sup.2可能是氢；C.sub.1-C.sub.8烷基；苯基(C.sub.1-C.sub.4)烷基或取代的苯基(C.sub.1-C.sub.4)烷基，其中苯基可以有一到三个来自C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，氟，氯或溴的取代基；苯基或取代苯基，其中苯基取代基与取代苯基(C.sub.1-C.sub.4)烷基相同；2-或4-嘧啶基；吡嗪基；咪唑基；C.sub.1-C.sub.4烷酰基；卤代或二卤代-(C.sub.1-C.sub.4)烷酰基，其中卤是氟或氯；苯甲酰基或在苯环上被一或两个C.sub.1-C.sub.4烷基取代的苯甲酰基；C.sub.1-C.sub.4烷酰氧基；C.sub.1-C.sub.4烷基氨基(C.sub.1-C.sub.4烷酰基；C.sub.1-C.sub.4烷氧羰基；C.sub.1-C.sub.4烷基氨基羰基；苯基氨基羰基，其中苯基可能有一到三个C.sub.1-C.sub.4烷基取代基；苯氧基或萘氧基-(C.sub.1-C.sub.4)烷基，其中苯基或萘基环可能被一到三个C.sub.1-C.sub.4烷基取代基取代；C.sub.1-C.sub.4烷基磺酰基；(C.sub.1-C.sub.4)烷基-或N-二(C.sub.1-C.sub.4烷基)羧酰胺基(C.sub.1-C.sub.4)烷基；N-苯基或取代苯基-羧酰胺-(C.sub.1-C.sub.4)烷基，其中苯基可以像上述的C.sub.1-C.sub.4烷基取代苯基一样被取代；氰基；两个N原子被C.sub.1-C.sub.4烷基取代的氨基甲酸酰基；和C.sub.1-C.sub.4烷基脲基；以及R.sup.3和R.sup.4独立地选自氢，C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，氟和氯，或它们的酸加成盐。具有特定R.sup.2值的I和II式化合物是抗心律失常或抗缺血剂。其余的R.sup.2值提供了I和II式中间体化合物。本文还披露了一种新型的四氢-3-取代-7-取代-1H[1,2,5]三唑环[1,2-a][1,2,4]苯并三嗪，其中7取代基可以是--SMe，--Cl或Br，而3取代基与上述I和II式中的R.sup.2相同。这些化合物也用作上述II式抗心律失常剂的中间体。

  公开号：

  US04935515A1
• 作为产物：
  描述：

  hexahydro-5-(phenylmethyl)-1H-1,2,5-triazepine dihydrochloride 、 1-氟-2-硝基苯 、 N,N-二异丙基乙胺 在 氯仿 、 sodium hydroxide 、 magnesium sulfate 、 甲苯 、 ether-heptane 、 chloroform-ether-heptane 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以gave pure titled product, mp=90°-92°的产率得到Hexahydro-1-(2-nitrophenyl)-5-(phenylmethyl)-1H-1,2,5-triazepine
  参考文献：
  名称：

  2,3,4,5-tetrahyd

  摘要：

  本文披露了新型的1,2,3,4,5,6-六氢[1,3,6]三唑环[1,2-a]苯并咪唑的I和II式：其中R.sup.1可能是苯基，m-或p-硝基苯基，m-或p-甲基磺酰氨基苯基，萘基，萘单取代硝基或甲基磺酰氨基，苯并呋喃基，2-嘧啶基，2-或4-吡啶基，2-或4-萘啉基，吡嗪基，异喹啉基或喹啉基；R.sup.2可能是氢；C.sub.1-C.sub.8烷基；苯基(C.sub.1-C.sub.4)烷基或取代的苯基(C.sub.1-C.sub.4)烷基，其中苯基可以有一到三个来自C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，氟，氯或溴的取代基；苯基或取代苯基，其中苯基取代基与取代苯基(C.sub.1-C.sub.4)烷基相同；2-或4-嘧啶基；吡嗪基；咪唑基；C.sub.1-C.sub.4烷酰基；卤代或二卤代-(C.sub.1-C.sub.4)烷酰基，其中卤是氟或氯；苯甲酰基或在苯环上被一或两个C.sub.1-C.sub.4烷基取代的苯甲酰基；C.sub.1-C.sub.4烷酰氧基；C.sub.1-C.sub.4烷基氨基(C.sub.1-C.sub.4烷酰基；C.sub.1-C.sub.4烷氧羰基；C.sub.1-C.sub.4烷基氨基羰基；苯基氨基羰基，其中苯基可能有一到三个C.sub.1-C.sub.4烷基取代基；苯氧基或萘氧基-(C.sub.1-C.sub.4)烷基，其中苯基或萘基环可能被一到三个C.sub.1-C.sub.4烷基取代基取代；C.sub.1-C.sub.4烷基磺酰基；(C.sub.1-C.sub.4)烷基-或N-二(C.sub.1-C.sub.4烷基)羧酰胺基(C.sub.1-C.sub.4)烷基；N-苯基或取代苯基-羧酰胺-(C.sub.1-C.sub.4)烷基，其中苯基可以像上述的C.sub.1-C.sub.4烷基取代苯基一样被取代；氰基；两个N原子被C.sub.1-C.sub.4烷基取代的氨基甲酸酰基；和C.sub.1-C.sub.4烷基脲基；以及R.sup.3和R.sup.4独立地选自氢，C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，氟和氯，或它们的酸加成盐。具有特定R.sup.2值的I和II式化合物是抗心律失常或抗缺血剂。其余的R.sup.2值提供了I和II式中间体化合物。本文还披露了一种新型的四氢-3-取代-7-取代-1H[1,2,5]三唑环[1,2-a][1,2,4]苯并三嗪，其中7取代基可以是--SMe，--Cl或Br，而3取代基与上述I和II式中的R.sup.2相同。这些化合物也用作上述II式抗心律失常剂的中间体。

  公开号：

  US04935515A1

文献信息

• 1,2,3,4,5,6-hexahydro[1,3,6]triazocino[1,1-a]benzimidazoles
  申请人：American Home Products

  公开号：US04882323A1

  公开（公告）日：1989-11-21

  Disclosed herein are novel 1,4-substituted-2,3,5,6-tetrahydro[1,3,6]triazocino[1,2-a]benzimidazole of Formulas I and II: ##STR1## wherein R.sup.1 may be phenyl, m- or p-nitrophenyl, m- or p-methylsulfonylaminophenyl, naphthyl, naphthyl mono-substituted by nitro or methylsulfonylamino, benzofurazanyl, 2-pyrimidinyl, 2- or 4-pyridinyl, 2- or 4-naphthyridinyl, pyrazinyl, isoquinolinyl, or quinolinyl; R.sup.2 may be hydrogen; C.sub.1 -C.sub.8 alkyl; C.sub.1 -C.sub.4 alkylphenyl or C.sub.1 -C.sub.4 alkyl-substituted-phenyl, in which phenyl may have one to three substituents selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, fluorine, chlorine or bromine; phenyl or substituted-phenyl in which the phenyl substituents are the same as for c.sub.1 -C.sub.4 alkyl-substituted-phenyl; 2- or 4-pyrimidinyl; pyrazinyl; imidazolyl; C.sub.1 -C.sub.4 alkanoyl; halo or dihalo-(C.sub.1 -C.sub.4)alkanoyl, in which halo is fluoro or chloro; benzoyl or benzoyl substituted on the phenyl ring by one or two C.sub.1 -C.sub.4 alkyl groups; C.sub.1 -C.sub.4 alkanoyloxy; C.sub.1 -C.sub.4 alkylamino(C.sub.1 -C.sub.4)alkanoyl; C.sub.1 -C.sub.4 alkyloxycarbonyl; C.sub.1 -C.sub.4 alkylaminocarbonyl; phenylaminocarbonyl in which phenyl may have one to three C.sub.1 -C.sub.4 alkyl groups; phenyloxy or naphthyloxy(C.sub.1 -C.sub.4)alkyl in which the phenyl or naphthyl ring may be substituted by one to three C.sub.1 - C.sub.4 alkyl groups; C.sub.1 -C.sub.4 alkylsulfonyl; N-(C.sub.1 -C.sub.4) alkyl- or N-(C.sub.1 -C.sub.4) dialkylcarboxamido(C.sub.1 -C.sub.4)alkyl; N-phenyl or substituted phenyl-carboxamido(C.sub.1 -C.sub.4)alkyl in which phenyl may be substituted as above for C.sub.1 -C.sub.4 alkyl-substituted phenyl; cyano; amidino in which each N atom is substituted by a C.sub.1 -C.sub.4 alkyl group; and C.sub.1 -C.sub.4 alkylguanidino; and R.sup.3 and R.sup.4 are, independently, selected from hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, fluorine and chlorine, or acid addition salts thereof. Compounds of formulas I and II having certain values of R.sup.2 are antiarrhythmic or antiischaemic agents. The remaining values of R.sup.2 provide intermediate compounds of formulas I and II. Also disclosed herein a novel tetrahydro-3-substituted-7-substituted-1H-[1,2,5]triazepino[1,2-a][1,2,4]b enzotriazines, wherein the 7 substituent may be --SMe, .dbd.S, .dbd.O, Cl or Br and the 3 substituent is the same as R.sup.2 in formulas I and II above. These componds also serve as intermediates for the production of the antiarrhythmic agents of formula II above.

  本文揭示了新颖的1,4-取代-2,3,5,6-四氢[1,3,6]三唑吲哚[1,2-a]苯并咪唑酮的化合物I和II的结构如下：其中R.sup.1可能是苯基、间或对硝基苯基、间或对甲基磺酰氨基苯基、萘基、萘基单取代的硝基或甲基磺酰氨基、苯并呋喃基、2-嘧啶基、2-或4-吡啶基、2-或4-萘啶基、吡嗪基、异喹啉基或喹啉基；R.sup.2可能是氢、C.sub.1-C.sub.8烷基、C.sub.1-C.sub.4烷基苯基或C.sub.1-C.sub.4取代苯基，其中苯基可能有来自C.sub.1-C.sub.4烷基、C.sub.1-C.sub.4烷氧基、氟、氯或溴的一到三个取代基；苯基或取代苯基，其中苯基取代基与C.sub.1-C.sub.4取代苯基相同；2-或4-嘧啶基；吡嗪基；咪唑基；C.sub.1-C.sub.4酰基；卤代或二卤代-(C.sub.1-C.sub.4)酰基，其中卤是氟或氯；苯甲酰基或苯甲酰基在苯环上取代一个或两个C.sub.1-C.sub.4烷基；C.sub.1-C.sub.4烷酰氧基；C.sub.1-C.sub.4烷基氨基(C.sub.1-C.sub.4)酰基；C.sub.1-C.sub.4烷氧羰基；C.sub.1-C.sub.4烷基氨基羰基；苯基氨基羰基，其中苯基可能有来自C.sub.1-C.sub.4烷基的一到三个取代基；苯氧基或萘氧基(C.sub.1-C.sub.4)烷基，其中苯基或萘基环可能被一到三个C.sub.1-C.sub.4烷基取代；C.sub.1-C.sub.4烷基磺酰基；N-(C.sub.1-C.sub.4)烷基-或N-(C.sub.1-C.sub.4)二烷基羧胺基(C.sub.1-C.sub.4)烷基；N-苯基或取代苯基-羧胺基(C.sub.1-C.sub.4)烷基，其中苯基可能被上述C.sub.1-C.sub.4取代苯基取代；氰基；酰胺基，其中每个N原子被C.sub.1-C.sub.4烷基取代；和C.sub.1-C.sub.4烷基胍胺基；R.sup.3和R.sup.4独立地选择自氢、C.sub.1-C.sub.4烷基、C.sub.1-C.sub.4烷氧基、氟和氯，或其酸盐。具有特定R.sup.2值的化合物I和II是抗心律失常或抗缺血药物。R.sup.2的其余值提供化合物I和II的中间体。本文还揭示了一种新颖的四氢-3-取代-7-取代-1H-[1,2,5]三唑二氮杂苯并三嗪，其中7位取代基可能是--SMe、.dbd.S、.dbd.O、氯或溴，3位取代基与上述化合物I和II中的R.sup.2相同。这些化合物也可用作上述抗心律失常药物的中间体的生产。
• US4882323A
  申请人：——

  公开号：US4882323A

  公开（公告）日：1989-11-21
• US4935515A
  申请人：——

  公开号：US4935515A

  公开（公告）日：1990-06-19
• 2,3,4,5-tetrahyd
  申请人：American Home Products Corporation

  公开号：US04935515A1

  公开（公告）日：1990-06-19

  Disclosed herein are novel 1,2,3,4,5,6-hexahydro[1,3,6]triazocino[1,2-a]benzimidazole of Formulas I and II: ##STR1## wherein R.sup.1 may be phenyl, m- or p-nitrophenyl, m- or p-methylsulfonylaminophenyl, napthtyl, naphthyl mono-substituted by nitro or methylsulfonylamino, benzofurazanyl, 2-pyrimidinyl, 2- or 4-pyridinyl, 2- or 4-naphthyridinyl, pyrazinyl, isoquinolinyl, or quinolinyl; R.sup.2 may be hydrogen; C.sub.1 -C.sub.8 alkyl; phenyl(C.sub.1 -C.sub.4)alkyl or substituted-phenyl(C.sub.1 -C.sub.4)alkyl, in which phenyl may have one to three substituents selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, fluorine, chlorine or bromine; phenyl or substituted-phenyl in which the phenyl substituents are the same as for substituted-phenyl (C.sub.1 -C.sub.4)alkyl; 2- or 4-pyrimidinyl; pyrazinyl; imidazolyl; C.sub.1 -C.sub.4 alkanoyl; halo or dihalo-(C.sub.1 -C.sub.4)alkanoyl, in which halo is fluoro or chloro; benzoyl or benzoyl substituted on the phenyl ring by one or two C.sub.1 -C.sub.4 alkyl groups; C.sub.1 -C.sub.4 alkanoyloxy; C.sub.1 -C.sub.4 alkylamino(C.sub.1 -C.sub.4 alkanoyl; C.sub.1 -C.sub.4 alkyloxycarbonyl; C.sub.1 -C.sub.4 alkylaminocarbonyl; phenylaminocarbonyl in which phenyl may have one to three C.sub.1 -C.sub.4 alkyl groups; phenyloxy or naphthyloxy-(C.sub.1 -C.sub.4)alkyl in which the phenyl or naphthyl ring may be substituted by one to three C.sub.1 -C.sub.4 alkyl groups; C.sub.1 -C.sub.4 alkylsulfonyl; (C.sub.1 -C.sub.4)alkyl- or N-di-(C.sub.1 -C.sub.4 alkyl)carboxamido(C.sub.1 -C.sub.4)alkyl; N-phenyl or substituted phenyl-carboxamido-(C.sub.1 -C.sub.4)alkyl in which phenyl may be substituted as above for C.sub.1 -C.sub.4 alkyl-substituted phenyl; cyano; amidino in which each N atom is substituted by a C.sub.1 -C.sub.4 alkyl group; and C.sub.1 -C.sub.4 alkylguanidino; and R.sup.3 and R.sup.4 are, independently, selected from hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, fluorine and chlorine, or acid addition salts thereof. Compounds of formulas I and II having certain values of R.sup.2 are antiarrhythmic or antiischaemic agents. The remaining values of R.sup.2 provide intermediate compounds of formulas I and II. Also disclosed herein a novel tetrahydro-3-substituted-7-substituted-1H[1,2,5]triazepino[1,2-a][1,2,4]be nzotriazines, wherein the 7 substituent may be --SMe, --Cl or Br and the 3 substituent is the same as R.sup.2 in formulas I and II above. These compounds also serve as intermediates for the production of the antiarrhythmic agents for formula II above.

  本文披露了新型的1,2,3,4,5,6-六氢[1,3,6]三唑环[1,2-a]苯并咪唑的I和II式：其中R.sup.1可能是苯基，m-或p-硝基苯基，m-或p-甲基磺酰氨基苯基，萘基，萘单取代硝基或甲基磺酰氨基，苯并呋喃基，2-嘧啶基，2-或4-吡啶基，2-或4-萘啉基，吡嗪基，异喹啉基或喹啉基；R.sup.2可能是氢；C.sub.1-C.sub.8烷基；苯基(C.sub.1-C.sub.4)烷基或取代的苯基(C.sub.1-C.sub.4)烷基，其中苯基可以有一到三个来自C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，氟，氯或溴的取代基；苯基或取代苯基，其中苯基取代基与取代苯基(C.sub.1-C.sub.4)烷基相同；2-或4-嘧啶基；吡嗪基；咪唑基；C.sub.1-C.sub.4烷酰基；卤代或二卤代-(C.sub.1-C.sub.4)烷酰基，其中卤是氟或氯；苯甲酰基或在苯环上被一或两个C.sub.1-C.sub.4烷基取代的苯甲酰基；C.sub.1-C.sub.4烷酰氧基；C.sub.1-C.sub.4烷基氨基(C.sub.1-C.sub.4烷酰基；C.sub.1-C.sub.4烷氧羰基；C.sub.1-C.sub.4烷基氨基羰基；苯基氨基羰基，其中苯基可能有一到三个C.sub.1-C.sub.4烷基取代基；苯氧基或萘氧基-(C.sub.1-C.sub.4)烷基，其中苯基或萘基环可能被一到三个C.sub.1-C.sub.4烷基取代基取代；C.sub.1-C.sub.4烷基磺酰基；(C.sub.1-C.sub.4)烷基-或N-二(C.sub.1-C.sub.4烷基)羧酰胺基(C.sub.1-C.sub.4)烷基；N-苯基或取代苯基-羧酰胺-(C.sub.1-C.sub.4)烷基，其中苯基可以像上述的C.sub.1-C.sub.4烷基取代苯基一样被取代；氰基；两个N原子被C.sub.1-C.sub.4烷基取代的氨基甲酸酰基；和C.sub.1-C.sub.4烷基脲基；以及R.sup.3和R.sup.4独立地选自氢，C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，氟和氯，或它们的酸加成盐。具有特定R.sup.2值的I和II式化合物是抗心律失常或抗缺血剂。其余的R.sup.2值提供了I和II式中间体化合物。本文还披露了一种新型的四氢-3-取代-7-取代-1H[1,2,5]三唑环[1,2-a][1,2,4]苯并三嗪，其中7取代基可以是--SMe，--Cl或Br，而3取代基与上述I和II式中的R.sup.2相同。这些化合物也用作上述II式抗心律失常剂的中间体。